AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03779971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil Containing Diet
Description: Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
Study NCT03779971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chickpea Containing Diet
Description: Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
Study NCT01357421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT301
Description: Single iv dose of TT301
Study NCT01357421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single iv dose of 0.9% sodium chloride for injection USP
Study NCT02678143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study NCT02678143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02678143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02678143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT02678143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02678143 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Study NCT02678143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplant
Study NCT00121693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy (listening to specific music)
Description: Listening to Music
Study NCT00612261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous Crossing Sheathotomy
Description: In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
Study NCT00612261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Triamcinolone Acetonide Injection
Description: The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
Study NCT01497496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
Study NCT00643903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral coping effectiveness training
Description: Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
Study NCT00643903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard of care for HIV infections.
Study NCT00643903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single group workshop on coping effectiveness training
Description: Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
Study NCT01271985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PolyPill
Description: A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
Study NCT01271985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal care
Description: Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
Study NCT04387604 — intervention group
Intervention type: DRUG
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Description: PRN regimen. Treatment Schedule Repeat injections at every 4-week visit if eye improves or worsens (defined as ≥5 letter change from last injection or ≥10% CST change on OCT from last injection or CSF>300 μm at any timepoint).~Defer injections if either BCVA of 85 letters and OCT CSF normal (CSF≤300 μm and non-existent intra- or sub-retinal fluid); or OCT CSF normal (CSF≤300 μm) and stable BCVA (defined as \< 5 letters change from last injection) after two consecutive injections during the first 24 weeks, or after one injection if the initial stability period has already been achieved (OCT CSF normal and stable BCVA).~Resume injections if BCVA or OCT worsens.
Study NCT03113461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: non-invasive positive airway pressure applied using an oronasal mask
Study NCT01174511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A -1 Cool Cream,Vaselin ointment
Description: A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
Study NCT01174511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A -1 Cool Cream,Vaselin ointment
Description: A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
Study NCT02906787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAS+
Description: The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
Study NCT02906787 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SC
Description: Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
Study NCT02638350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strategy with lung ultrasound
Description: Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema.
Study NCT02422407 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Salivary Gland
Study NCT04416061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID 19 Diagnostic Test
Description: COVID 19 Diagnostic Test
Study NCT03800290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clenbuterol Hydrochloride
Description: Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
Study NCT03800290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
Study NCT01871636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection
Description: Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
Study NCT01871636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Waterjet-assisted ESD
Description: The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
Study NCT01871636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HybridKnife
Description: The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
Study NCT03662217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm-based diet
Description: Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
Study NCT03662217 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADA- based diet
Description: The American standard of care dietary guidelines for diabetes.
Study NCT02834416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Group Exercise
Description: The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
Study NCT02834416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Exercise
Description: The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
Study NCT04180150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334
Description: TQ-A3334 is a kind of TLR7 receptor agonist.
Study NCT04180150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a treatment which is designed to have no therapeutic value.
Study NCT04180150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir Tablet
Description: Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
Study NCT04180150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir Tablet
Description: Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
Study NCT01133379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12027-019
Description: Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
Study NCT01133379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12027-020
Description: Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
Study NCT01133379 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 12027-021
Description: Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
Study NCT02450604 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Diagnosis of Fabry disease
Description: The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
Study NCT00687440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m\^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks.
Study NCT00687440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
Study NCT00687440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
Study NCT02351479 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hula
Study NCT03332329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir is used for 96 weeks
Study NCT03332329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulating Factor
Description: Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
Study NCT03332329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y peginterferon alfa-2b
Description: Y peginterferon alfa-2b is used for 96 weeks
Study NCT03332329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBV vaccine
Description: 60ug HBV vaccine is used every four week for 24 weeks
Study NCT03719638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: D-blade of videolaryngoscope
Description: intubation will be done using d-blade of videolaryngoscope
Study NCT03719638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: simulated difficult airway
Description: extension of head will be limited by using collar.
Study NCT03719638 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh videolaryngoscope
Description: intubation will be done using macintosh videolaryngoscope
Study NCT03113461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: non-invasive positive airway pressure applied using an oronasal mask
Study NCT02681029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blastocyte Transferring
Description: Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
Study NCT02681029 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Embryo Transferring
Description: Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
Study NCT01809600 — intervention group
Intervention type: OTHER
Intervention: No intervention (observational study)
Study NCT04266717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Play Intervention
Description: Baby Play Intervention involves teaching parents targeted ways they can handle, position, and play with young infants that aim to provide infants enhanced early opportunities to learn to control their bodies and interact with objects. These abilities are associated with future motor, cognitive, and language outcomes. Parents will be asked to perform the intervention activities 20 minutes daily and to log their activity performance weekly.
Study NCT04266717 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Milestone Education
Description: Parents in the Milestone Education Intervention group will receive information regarding milestones expected based on infants' CA. This information is based on forms from the Centers for Disease Control and Prevention (CDC) and The American Academy of Pediatrics (AAP). This will help parents understand the milestones typically observed at the their child's CA and reflects the education parents receive from healthcare providers. Parents will be asked to provide their infants opportunities to perform these milestone behaviors 20 minutes daily and to log their activity performance weekly.
Study NCT03824249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry
Description: Performance of indirect calorimetry in Canopy mode.
Study NCT03610269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00026 (Pulse CO-Oximeter and sensor)
Description: Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
Study NCT03298425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment NMES
Description: Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
Study NCT03298425 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NMES
Description: TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
Study NCT03902353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.
Description: will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
Study NCT02668653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study NCT01062048 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
Study NCT01062048 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Description: Sulfonylurea administered in general use according to the local label
Study NCT01062048 — intervention group
Intervention type: BIOLOGICAL
Intervention: Insulin
Description: Insulin administered in general use according to the local label
Study NCT02944253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low energy diet 70 gram carbohydrates
Description: isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates
Study NCT02944253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low energy diet 100 gram carbohydrates
Description: isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women
Study NCT02944253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low energy diet 130 gram carbohydrates
Description: isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide s.c.
Description: Administered to Cushing's disease participants.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pasireotide s.c.
Description: Administered to Cushing's disease participants.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Participant switched to liraglutide if sitagliptin was found not to be effective.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin
Description: Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Administered to Acromegaly participants.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pasireotide LAR
Description: Administered to Acromegaly participants.
Study NCT02060383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin.